Yale Investigators' Lead Grant Awarded as Part of the NIH HEAL Initiative on Opioids
Dr. Gail D’Onofrio, Professor of Emergency Medicine and Public Health and Dr. David Fiellin, Professor of Medicine, Emergency Medicine and Public Health are lead investigators in a $25.5 Million study being conducted by the National Drug Abuse Treatment Clinical Trials Network’s New England Consortium Node.
Yale and Mayo Clinic Awarded FDA Grant to Study Opioid Prescribing and Use
Yale University and Mayo Clinic have been awarded a grant for up to $5.3 million over two years by the U.S. Food and Drug Administration (FDA) to study patients’ experiences with pain and use of opioids prescribed for acute pain. This project is part of the Center of Excellence in Regulatory Science and Innovation (CERSI), a joint effort between Yale, Mayo Clinic, and the FDA. The study will be conducted in collaboration with Regional Health of Rapid City, S.D., and University of Alabama at Birmingham (UAB).
Krumholz, Spatz receive funding to develop new 24/7 blood pressure monitor
The National Institute of Biomedical Imaging and Bioengineering has awarded a $1.2 million, four-year grant to investigators at Texas A&M University and Yale University for the development of a wrist-worn, cuffless blood pressure monitoring system.
Medical faculty elected to the American Society for Clinical Investigation
Drs. Daniel Greif, Cary Gross, Chirag Parikh, and Joseph Ross of Yale School of Medicine have been elected to the American Society for Clinical Investigation (ASCI). One of the nation’s oldest and most prestigious medical honor societies, ASCI supports the work of top physician-scientists whose research improves human health.
Most studies misuse data set, researchers find
A team of researchers, including a professor and a postdoctoral researcher at Yale, recently published a paper with troubling findings: The vast majority of a set of studies conducted with data from a widely used public data set are not meeting required methodological standards. According to the study, which was published in the Nov. 28 issue of JAMA, 102 of 120 studies — selected at random and intended as a representative sample of the 1,084 studies published using an open-source database in 2015–16 — did not adhere to one or more required research practices.
Yale launches new program in addiction medicine
The Yale School of Medicine Section of General Internal Medicine has established a new program — the Yale Program in Addiction Medicine. The multi-disciplinary clinical, educational, and research program will further enhance Yale’s portfolio of state-of-the-art addiction research and patient care, while increasing the pipeline of physicians trained in evidence-based strategies to tackle the opioid crisis and other addiction-related health issues.
Yale experts selected to conduct medical device surveillance research
Two projects conducted by Yale School of Medicine faculty have been selected as Demonstration Projects by NEST, the National Evaluation System for Health Technology, which was established by the Medical Device Innovation Consortium and funded by FDA.
Videogame boosts sex health IQ and attitudes in minority teens
A videogame designed by Yale researchers to promote health and reduce risky behavior in teens improves sexual health knowledge and attitudes among minority youth, according to a new study. The findings validate the value of the videogame as a tool to engage and educate teens at risk for HIV and other sexually transmitted infections (STIs), said the researchers.
Pushing Hospitals To Reduce Readmissions Hasn't Increased Deaths
Too often, people return home from the hospital only to find themselves heading back soon after. Sometimes the need arises because, despite the best care, it is difficult to slow the progression of disease. But other times, it's because we in the health care system fail to communicate, coordinate and orchestrate the care that people need to successfully make the transition from hospital to home.
Heart study finds faulty link between biomarkers and clinical outcomes
Surrogate endpoints (biomarkers), which are routinely used in clinical research to test new drugs, should not be trusted as the ultimate measure to approve new health interventions in cardiovascular medicine, according to a recent study by Yale School of Medicine researchers in JAMA.
Yale experts question push for ‘abuse-deterrent’ Rx opioids
In response to the rise in opioid overdose deaths nationwide, pharmaceutical companies have developed formulations of prescription opioids designed to prevent tampering or abuse. These “abuse-deterrent” forms, however, are expensive and may not actually have the intended effect, say experts from Yale School of Medicine.
Life expectancy for HIV patients has increased by 10 years in U.S. and Europe
Life expectancy for 20-year-olds initiating treatment for HIV has increased by about a decade in the European Union and North America since the introduction of antiretroviral therapy in the mid-1990s, according to a study co-authored by Yale researcher Dr. Amy Justice and published in The Lancet HIV. The increases are among treated individuals compared with untreated individuals, the global team of researchers said.
Trump wants faster FDA action, but 1 in 3 drugs have safety issues after approval
President Trump wants the Food and Drug Administration to approve drugs faster, but researchers at the Yale School of Medicine found that nearly a third of medications that reached the market from 2001 through 2010 had major safety issues years after they became widely available to patients.
GHLI announces junior faculty awards
The Yale Global Health Leadership Institute (GHLI) announced this year’s recipients of the Hecht-Albert Pilot Innovation Award for Junior Faculty. The award is granted to junior faculty who engage students to advance new research and educational projects in global health at Yale.
FDA approves drugs more quickly than peer agency in Europe
The U.S. Food and Drug Administration (FDA) reviews and approves new medicines in a shorter timeframe than its peer agency in Europe, the European Medicines Agency (EMA), says a Yale researcher. This finding comes at a time when the FDA is under renewed pressure to streamline and speed up its approval process, and provides data to inform ongoing policy discussions.